Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus

Next Previous
Trial Profile

A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Moxidectin (Primary) ; Ivermectin
  • Indications Onchocerciasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Medicines Development Limited; Pfizer; Wyeth

Most Recent Events

  • 13 Jun 2018 According to a United States (U.S.) Food and Drug Administration (FDA) media release, the agency has approved moxidectin 8 mg oral for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older. The approval was based on data from this and another trial (CT profile 700244968).
  • 18 Jan 2018 Primary endpoint (Skin microfilaria density (mf/mg)) has been met, according to the results published in The Lancet
  • 18 Jan 2018 Results published in The Lancet.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top